Study Tests Immunotherapy in People with Cancer and Autoimmune Diseases

If you are an individual living with both scleroderma and cancer, you may be eligible for a new immunotherapy study sponsored by the National Cancer Institute.

The National Cancer Institute has sponsored a clinical trial to test an immunotherapy drug (an anti-PD1 inhibitor, called nivolumab or Opdivo) in patients who have both cancer and an autoimmune disease, such as scleroderma. The trial will include 260 people with severe cancer and an autoimmune disease, and 36 spots are reserved for individuals with advanced cancer and scleroderma. The researchers hope to learn more about how to treat patients with cancer and rare conditions like scleroderma. The scientific evidence could help develop new treatments for individuals with scleroderma and help doctors to better manage and prevent side effects from promising new treatments that are given to those patients with autoimmune conditions who are otherwise good candidates for immune-based treatment of their cancer.

There are centers across the country, which can be seen in the link below. The trial is open at major cancer centers throughout the United States and at Princess Margaret in Toronto, Canada. Regardless of location, patients will not have to pay for the study drug at all and treatment should be covered by insurance. Visit the link to learn more about the trial.

READ

The National Scleroderma Foundation's Advocacy Team Scores Big for Scleroderma Research

If you wrote to your Senators urging them to include scleroderma on the PRMRP, we are pleased to say our efforts paid off! The Senate Appropriation Committee released their draft bill for the Peer-Reviewed Medical Research Program, and scleroderma was included as a condition eligible for the study. Thank you to everyone who advocated for scleroderma. This is a big win for the community, and each step brings us closer to finding a cure.

The 20%: A Virtual Support Group for Males Living with Scleroderma

ZOOM: August 24, 2022; 7 p.m. EST

Scleroderma diagnoses are less common amongst men. In fact, only 20% of individuals living with scleroderma are male. We have designed a support group, especially for males with scleroderma. In it, you will learn scleroderma tips and resources and find support from others in your position. Each meeting, we will focus on a different topic from mental health to intimacy and so much more. The group meets on the fourth Wednesday of the month (with some exceptions) from 7 to 8 p.m. Eastern.

REGISTER

El Grupo Bilingüe de Apoyo

El Grupo Bilingüe de Apoyo de la Fundación Nacional de Esclerodermia le invita a su evento educativo vía zoom “Hipertensión Pulmonar,” el próximo 13 de agosto del 2022.

10:00 am (Costa Rica)
11:00 am (Colombia) (Ecuador) (Mexico) (Panama) (Peru) 12:00 pm (Bolivia) (Chile) (USA)
1:00 pm (Argentina)
6:00 pm (España) 

Por favor envíe sus preguntas al correo electrónico miamiradgroup@gmail.com antes de la reunión. A continuación, vínculo para registrarse al evento. 

REGISTRO

Individuals With Scleroderma Without Lung Disease Needed to Study a Non-invasive Lung Function Test to Predict Early Airway Injury.

National Jewish Health Rheumatology investigators are conducting a study of individuals with scleroderma without known lung disease to determine if a new lung function test (called Lung Clearance Index) can detect subtle small airway abnormalities that may predict development of lung scarring.
ClinicalTrials.gov NCT 04535245
 

Qualifications include:

-Diagnosis of scleroderma without lung disease by a board-certified rheumatologist.
-Men or women ages 21-75
-Must be able to perform seated breathing tests.

For more information and to enroll in this study, please contact:

Mary Gill RN at Gillm@njhealth.org or Principal investigator Richard Meehan MD at (303) 398-1443.  

Co-investigators: Liudmila Kastsianok MD, Mehrnaz Maleki MD, Lauren Zell-Baan MPH, PhDc, and Kristen Demoruelle MD PhD.

Now Accepting Scleroderma Research Grant Applications

If you hold a faculty-equivalent position and are newly pursuing a career in scleroderma-related research, apply to our New Investigators Grant. Anyone who is an established researcher both inside and outside the field of scleroderma research who wishes to propose pilot studies to obtain preliminary data dealing with a highly innovative and/or highly relevant theme related to scleroderma should apply for our Established Investigator Grants.

To learn more about our research grants or apply, visit our website. We will accept applications until September 15, 2022.

Fathers with Scleroderma Needed for Survey Research Study on Parenting

Researchers from the University of New Mexico are seeking participants for a study exploring the impact of symptoms, such as pain and fatigue, on parenting in fathers who have systemic sclerosis (scleroderma). Fathers with scleroderma who have children 18 years and younger living with them may be eligible to participate in the survey study. This study was approved by the UNM Human Research Review Committee (HRRC 21-209). For more information about the study and the eligibility requirements, please contact Janet Poole PhD, OTR/L at jpoole@salud.unm.edu or (505) 272-8276.

Gold 

Silver